Amoy Diagnostics Co., Ltd. Class A

Amoy Diagnostics Co., Ltd. Class A

SSZSE:300685
17.99
CNY
+0.03
(+0.17%)
0.87EPS
23.82P/E
8.32BMarket Cap
Apr 13Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.26
0.27
0.6
0.87
0.99
1.13
2.23
1.84
2.3
2.14
2.63
2.78
3.02
3.11
Basic EPS, GAAP
0.08
0.05
0.07
0.23
0.28
0.33
0.52
0.46
0.6
0.67
0.66
0.64
0.91
0.9
Free Cash Flow per Basic Share
-0.09
-0.08
-0.04
-0.05
0.21
0.14
0.49
0.41
0.23
0.18
0.64
0.76
0.74
- -
Dividend per Share
- -
0.01
0.01
- -
- -
0.05
0.1
0.1
0.14
0.13
0.14
0.15
0.3
0.47
Book Value per Share
0.13
0.3
0.83
1.06
1.67
1.95
2.27
2.83
3.42
3.77
4.27
4.63
5.25
5.04
Tangible Book Value per Share
0.08
0.25
0.73
1
1.63
1.91
2.23
2.79
3.37
3.65
4.15
4.52
5.14
4.93
Basic Weighted Avg Shares
292
389
293
291
334
389
259
396
399
394
396
398
397
386
Sales/Revenue/Turnover
74
107
177
253
330
439
578
728
917
842
1,044
1,109
1,198
1,202
Operating Margin (%)
23.86
17.36
10.23
19.69
33.48
31.07
27.13
29.99
28.88
20.2
28.48
27.56
34.36
36.12
Depreciation Expense
4
6
12
15
16
20
24
27
39
52
57
56
55
- -
Net Income, GAAP
22
19
21
67
94
127
135
180
240
264
261
255
361
346
Effective Tax Rate (%)
16.44
16.49
24.85
10.39
12.03
10.98
16.04
10.16
5.14
7.62
11.32
12.08
12.09
12.19
Profit Margin (%)
29.65
17.92
11.92
26.5
28.47
28.87
23.42
24.76
26.12
31.32
25.06
22.98
30.16
28.78
Working Capital
-3
6
120
169
470
508
657
857
1,061
1,193
1,446
1,594
1,875
1,852
LT Debt
11
18
- -
- -
- -
- -
- -
2
3
48
47
9
99
157
Total Equity
39
88
248
308
649
757
902
1,128
1,370
1,500
1,703
1,843
2,056
1,965
Return on Invested Capital (%)
33.22
16.27
7.81
19.2
19.33
18.14
16.31
17.8
19.21
18.28
16.19
14.07
18.05
16.98
Return on Capital (%)
59.17
23.23
13.4
23.98
19.46
17.93
16.18
17.76
19.17
18.03
15.85
13.99
17.86
17.02
Return on Common Equity (%)
77.98
30.18
12.84
24.43
19.66
18.03
16.33
17.76
19.22
18.42
16.33
14.37
18.53
17.97

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
14
15
11
LT Borrowings
182
180
153
LT Finance Leases
5
2
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
392
390
390
Market Capitalization
8,790
6,569
8,325

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,111
1,928
1,974
Cash, Cash Equivalents & STI
1,432
1,226
1,259
Accounts Receivable, Net
592
613
623
Inventories
46
46
42
Total Current Liabilities
139
125
122
Payables & Accruals
- -
- -
- -
ST Debt
14
15
11
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
26.01%
12.84%
11.54%
Free Cash Flow
-24.99%
41.67%
-2.33%
Net Income, GAAP
41.43%
16.26%
41.74%
Sales/Revenue/Turnover
22.01%
11.19%
8.01%
Total Cash Common Dividend
483.74%
30.56%
96.31%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
233
310
305
261
1,109
2025
272
307
- -
332
1,198
2026
260
299
310
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.16
0.2
0.21
0.07
0.64
2025
0.23
0.26
- -
0.25
0.91
2026
0.22
0.21
0.21
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.12
0.03
- -
0.15
2025
- -
0.24
- -
- -
0.3
2026
- -
0.46
- -
- -
- -

Company Description

CEO
Jie Min Luo
Full Time Employees
1,175
Sector
Health technology
Industry
Medical specialties
Address
39 Dingshan Road Xiamen FU China 361027
IPO Date
Aug 2, 2017
Website
amoydx.com
Business
Amoy Diagnostics Co., Ltd. develops and manufactures precision oncology diagnostic products primarily focused on molecular diagnostics for cancer care. Its main products include gene mutation detection kits, gene amplification detection kits, nucleic acid extraction kits, and comprehensive gene panels such as the AmoyDx homologous recombination deficiency (HRD) focus panel, HRD complete panel, and the CGP master panel that detect genomic signatures including HRD, MSI, TMB, and various gene mutations including EGFR, ALK, ROS1, KRAS, NRAS, BRAF, and more. The product portfolio also features PCR panels tailored for colorectal cancer, thyroid cancer, and other precision molecular tests designed to accelerate biomarker identification and cancer treatment research. Amoy Diagnostics operates a wide-ranging molecular diagnostic product line under its Super-ARMS and AmoyDx brands. Founded in 2008 and headquartered in Xiamen, China, Amoy Diagnostics has established a robust presence with extensive operations in China and expanding international reach in markets such as Japan, South Korea, and the Asia-Pacific region. The company prioritizes innovation, recently achieving milestone regulatory approvals including China’s first NGS-based companion diagnostic kit approved for both tissue and plasma samples, providing enhanced flexibility for clinical precision testing. Recent major developments include strategic partnerships and collaborations with leading pharmaceutical firms such as AstraZeneca under a Master Collaboration Agreement to develop companion diagnostic programs in China, the EU, and Japan; a collaborative agreement with Boehringer Ingelheim for companion diagnostic development for lung cancer therapies; and an MoU with Janssen Pharmaceutical Companies for strategic cooperation in biomarker research, patient management, and market access. Amoy Diagnostics also expanded its diagnostic offerings with the launch of advanced PCR panels for cancer mutation detection and has strengthened its global distribution network with over 100 distributors internationally. Its products have secured multiple Innovative Medical Device designations by China’s NMPA, underscoring its commitment to advancing precision oncology globally. The company continues focusing on product innovation, international market expansion, and deeper engagement with global biopharmaceutical partners to accelerate precision oncology solutions beyond China.